drugset / Trial / NCT05044871
Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer
Phase 2
Completed
108 enrolled
Tongji Hospital
Anhui Provincial Hospital · collabChongqing University Cancer Hospital · collabFirst Affiliated Hospital Xi'an Jiaotong University · collabFujian Cancer Hospital · collabHubei Cancer Hospital · collabPeking University Cancer Hospital & Institute · collabQilu Hospital of Shandong University · collabShandong Cancer Hospital and Institute · collabSun Yat-Sen University Cancer Center · collabUnion Hospital, Tongji Medical College · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is an open-label, multicenter, umbrella study aimed to evaluate the combined, biomarker-driven, targeted treatment efficiency of Pamiparib, Bevacizumab, Tislelizumab, and Nab-paclitaxel in patients with platinum-resistant recurrent ovarian cancer (PROC).
Timeline
- Start
- 2022-07-22
- Primary completion
- 2025-02-17
- Completion
- 2025-02-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Paclitaxel | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |
| Subject | Pamiparib | Small molecule | 40 mg | Oral |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |